Does the DEA Treat Ketamine Differently from Opioids
The DEA applies the same basic legal framework to ketamine prescribing and diversion as it applies to opioid prescribing and diversion, with several practical differences that reflect the different scheduling classification, the different clinical applications, and the different historical diversion patterns associated with the two drug categories.
The fundamental legal standard is identical: a prescription for any controlled substance must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. That standard applies to ketamine prescriptions with the same force it applies to opioid prescriptions, and the DEA’s authority to investigate and prosecute prescribing that falls outside that standard applies equally. The differences lie in the investigative tools, the monitoring intensity, and the specific clinical standards against which the prescribing is assessed.
Scheduling Differences and Their Practical Consequences
Ketamine’s Schedule III classification means that ketamine prescriptions are not subject to all of the same prescription requirements as Schedule II opioids. Ketamine prescriptions may be telephoned to pharmacies, may be refilled up to five times within six months, and are not subject to the same ARCOS monitoring intensity as Schedule II substances. These differences in prescription requirements create a regulatory environment in which ketamine prescribing is somewhat less visible to the DEA’s standard monitoring systems than Schedule II opioid prescribing.
The less intensive monitoring does not mean less rigorous legal standards. The usual course of professional practice standard applies with equal force to both drug categories. But the investigative pathway to identifying ketamine diversion may be different from the opioid investigation pathway: rather than PDMP outlier analysis driving the initial investigation, ketamine investigations are more likely to be triggered by facility-level inventory audits, theft reports, or complaints about specific clinical practices.
The Clinical Standard Differences
The clinical standard against which opioid prescribing is assessed is well-developed and extensively documented in the CDC guidelines, specialty society standards, and state medical board guidelines that have accumulated over decades of opioid prescribing regulation. The clinical standard against which ketamine prescribing is assessed is less settled, reflecting the relative novelty of ketamine’s expanded clinical applications and the ongoing development of clinical guidelines for ketamine infusion therapy and off-label prescribing.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196The absence of comprehensive clinical guidelines for all forms of ketamine prescribing creates both a challenge and an opportunity for practitioners and their defense counsel. The challenge is that the standard of care against which prescribing is assessed may be less clear than in the opioid context. The opportunity is that the less settled clinical landscape provides more room for the exercise of clinical judgment and the development of practice-specific protocols that the defense can present as reasonable professional practice.
Investigative Focus Differences
DEA opioid investigations have historically concentrated on individual prescribers whose PDMP data generates statistical outlier flags. DEA ketamine investigations have more commonly concentrated on clinic-level operations, because ketamine is typically administered in clinical settings rather than dispensed through retail pharmacies, and the inventory and billing records of ketamine clinics are the primary data source for diversion investigations.
A ketamine clinic that maintains inadequate controlled substance inventory records, that cannot reconcile its ketamine purchases against documented clinical administrations, or that bills for ketamine-related services without supporting clinical documentation has created the kind of record that triggers DEA and OIG investigation regardless of whether any individual practitioner’s prescribing volume generates a PDMP flag.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
Ketamine is treated differently from opioids in the specific investigative tools and monitoring mechanisms the DEA employs. It is not treated differently in the fundamental legal question: was the substance prescribed and administered for a legitimate medical purpose within the usual course of professional practice? That question is asked about ketamine with the same consequences as it is asked about opioids. The answer to it depends on the clinical record, the clinical standards, and the quality of the defense that addresses both.
The Convergence in Prosecution
When ketamine cases reach the prosecution stage, the legal framework converges with the opioid prosecution framework. The charges are typically drawn from the same statutes: 21 U.S.C. 841 for distribution outside the usual course of professional practice, and 18 U.S.C. 1347 for healthcare fraud if billing to federal programs was involved. The defenses are structured around the same elements: legitimate medical purpose, usual course of professional practice, clinical documentation, and the good faith of the prescribing decision. The trial dynamics, involving competing medical expert testimony about the clinical standard and the defendant’s compliance with it, are essentially identical to the dynamics in opioid fraud trials.
